TNAX Biopharma Corporation and IMIDomics Inc. have entered into a license agreement under which IMIDomics has exclusive worldwide rights to develop, manufacture, commercialize and sublicense TNAX’s anti-DNAM-1 mAbs targeting inflammatory diseases(Press Release).
目次